Author

K. Hioki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Temizoz· 2 shared K. J. Ishii· 2 shared K. Kobiyama· 2 shared A. Kumanogoh· 1 shared C. Coban· 1 shared C. T. Nguyen· 1 shared E. Kuroda· 1 shared E. Sag· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Temizoz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

5,6-dimethylxanthenone-4-acetic acid (DMXAA), a Partial STING Agonist, Competes for Human STING Activation

B. Temizoz, T. Shibahara, K. Hioki, T. Hayashi, K. Kobiyama, M. S. J. Lee, N. Surucu, E. Sag, A. Kumanogoh, M. Yamamoto, M. Gursel, S. Ozen, E. Kuroda, C. Coban, K. J. Ishii

This paper investigates DMXAA's partial STING agonist activity and develops HHMX, a derivative that antagonizes STING-mediated immune responses in both humans and mice.

bioRxiv · Dec 7, 2023 · PreprintImmunology

Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

K. Kobiyama, M. Imai, N. Jounai, M. Nakayama, K. Hioki, K. Iwatsuki-Horimoto, S. Yamayoshi, J. Tsuchida, T. Niwa, T. Suzuki, M. Ito, S. Yamada, T. Watanabe, M. Kiso, H. Negishi, , K. J. Ishii

This study optimizes an LNP-mRNA vaccine targeting SARS-CoV-2 RBD by removing reactogenic materials, improving immunogenicity and protection in macaques.

bioRxiv · Mar 4, 2021 · PreprintImmunology